Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy

[1]  Mehmet Kose,et al.  Pulmonary Langerhans cell histiocytosis , 2013, European Journal of Pediatrics.

[2]  M. Humbert,et al.  Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. , 2012, Chest.

[3]  M. Gatzoulis,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[4]  P. Pellikka,et al.  Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. , 2004, Mayo Clinic proceedings.

[5]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[6]  M. Gosselin,et al.  Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. , 2003, Chest.

[7]  P. Dartevelle,et al.  Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  P. Friedman,et al.  Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. , 1981, Medicine.

[9]  R. Kumar,et al.  Correction. , 2014, Journal of the American College of Cardiology.

[10]  G. Filippatos,et al.  Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .

[11]  M. Humbert,et al.  Severe pulmonary hypertension in histiocytosis X. , 2000, American journal of respiratory and critical care medicine.

[12]  L. Ackerson,et al.  Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. , 1996, American journal of respiratory and critical care medicine.